ArticlePloS one2013
The antifungal eugenol perturbs dual aromatic and branched-chain amino acid permeases in the cytoplasmic membrane of yeast.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 77 citations in OpenAlex.
- Application potential of a marine-derived halotolerant yeast in saline azo dye wastewater treatment: elucidating degradation pathways and osmo-adaptive strategies.Bioprocess and biosystems engineering · 2026Article
- Pathologic evaluation of Syzygium aromaticum essential oil against pulmonary aspergillosis in non-neutropenic immunosuppressed rabbits.Scientific reports · 2026Article
- Blocking the shikimate pathway amplifies the impact of carvacrol on biofilm formation inMicrobiology spectrum · 2025Article
- New antifungal strategies and drug development against WHO critical priority fungal pathogens.Frontiers in cellular and infection microbiology · 2025Review
- Research progress on the function and regulatory pathways of amino acid permeases in fungi.World journal of microbiology & biotechnology · 2024Review
- Cymoxanil disrupts RNA synthesis through inhibiting the activity of dihydrofolate reductase.Scientific reports · 2024Article
- Inhibitory Properties of Cinnamon Bark Oil against Postharvest PathogenJournal of fungi (Basel, Switzerland) · 2024Article
- The Antileishmanial Activity of Eugenol Associated with Lipid Storage Reduction Rather Than Membrane Properties Alterations.Molecules (Basel, Switzerland) · 2023Article
- Cinnamon Leaf and Clove Essential Oils Are Potent Inhibitors ofMicroorganisms · 2022Article
- Unravelling the Therapeutic Potential of Nano-Delivered Functional Foods in Chronic Respiratory Diseases.Nutrients · 2022Review
- Discovery of Natural Products With Antifungal Potential Through Combinatorial Synergy.Frontiers in microbiology · 2022Article
- Article
- Anticancer Properties of Eugenol: A Review.Molecules (Basel, Switzerland) · 2021Review
- Formulation, optimization, and nephrotoxicity evaluation of an antifungal in situ nasal gel loaded with voriconazole‒clove oil transferosomal nanoparticles.Drug delivery · 2021Article
- Development, optimization and characterization of nanoemulsion loaded with clove oil-naftifine antifungal for the management of tinea.Drug delivery · 2021Article
- Antioxidant Activities of a New Chemotype ofPlants (Basel, Switzerland) · 2020Article
- The Glycerol Phosphatase Gpp2: A Link to Osmotic Stress, Sulfur Assimilation and Virulence inFrontiers in microbiology · 2019Article
- Combined use of thermo-ultrasound and cinnamon leaf essential oil to inactivateJournal of food science and technology · 2018Article
- Commercial AHAS-inhibiting herbicides are promising drug leads for the treatment of human fungal pathogenic infections.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- Zinc oxide and silver nanoparticles toxicity in the baker's yeast, Saccharomyces cerevisiae.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eugenol is an aromatic component of clove oil that has therapeutic potential as an antifungal drug, although its mode of action and precise cellular target(s) remain ambiguous. To address this knowledge gap, a chemical-genetic profile analysis of eugenol was done using ∼4700 haploid Saccharomyces cerevisiae gene deletion mutants to reveal 21 deletion mutants with the greatest degree of susceptibility. Cellular roles of deleted genes in the most susceptible mutants indicate that the main targets for eugenol include pathways involved in biosynthesis and transport of aromatic and branched-chain amino acids. Follow-up analyses showed inhibitory effects of eugenol on amino acid permeases in the yeast cytoplasmic membrane. Furthermore, phenotypic suppression analysis revealed that eugenol interferes with two permeases, Tat1p and Gap1p, which are both involved in dual transport of aromatic and branched-chain amino acids through the yeast cytoplasmic membrane. Perturbation of cytoplasmic permeases represents a novel antifungal target and may explain previous observations that exposure to eugenol results in leakage of cell contents. Eugenol exposure may also contribute to amino acid starvation and thus holds promise as an anticancer therapeutic drug. Finally, this study provides further evidence of the usefulness of the yeast Gene Deletion Array approach in uncovering the mode of action of natural health products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.